Mariner LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 50.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 259,420 shares of the company's stock after purchasing an additional 87,321 shares during the quarter. Mariner LLC's holdings in Kenvue were worth $5,538,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Bard Financial Services Inc. grew its stake in Kenvue by 5.7% in the 3rd quarter. Bard Financial Services Inc. now owns 106,790 shares of the company's stock valued at $2,470,000 after acquiring an additional 5,750 shares during the period. Boyar Asset Management Inc. lifted its holdings in Kenvue by 7.2% in the 3rd quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company's stock valued at $675,000 after purchasing an additional 1,948 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Kenvue in the 3rd quarter valued at about $1,057,000. Tidal Investments LLC lifted its stake in Kenvue by 9.9% in the 3rd quarter. Tidal Investments LLC now owns 131,128 shares of the company's stock worth $3,033,000 after purchasing an additional 11,849 shares in the last quarter. Finally, Oddo BHF Asset Management Sas acquired a new position in shares of Kenvue during the 3rd quarter worth approximately $1,570,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on KVUE shares. Piper Sandler lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Barclays cut their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, Citigroup raised their price objective on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $24.42.
Check Out Our Latest Research Report on Kenvue
Kenvue Stock Down 0.5 %
KVUE stock traded down $0.11 during midday trading on Friday, hitting $22.65. The company's stock had a trading volume of 3,366,792 shares, compared to its average volume of 17,027,533. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a 50-day simple moving average of $23.01 and a 200-day simple moving average of $22.42. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $43.45 billion, a P/E ratio of 42.66, a PEG ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.62%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
